Sensus Healthcare closes $11m IPO

Sensus Healthcare (NSDQ:SRTSU) said today it closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each. The offering included a fully-exercised underwriters option of an additional 300,000 units at the IPO price, Sensus said. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The company said March 9 that it planned to float more than 1.8 million shares at $10 to $12 apiece, working out to a low-end raise of $18.2 million and a high end of $21.8 million. Later that month, Sensus postponed the IPO. Last month, Sensus scaled back, saying it planned to offer 1.75 million shares at $6.25 apiece, for gross proceeds of $10.9 million. The SRT-100 system has U.S. 510(k) clearance, CE Mark approval in the European Union and approvals from the China Food &Drug Administration and Health Canada; Sensus claims more than 200 installed devices in 11 countries. The company had planned to put $3 million of the IPO proceeds toward hiring new sales reps and a director of marketing, and another $3 million into R&D for new pr...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Funding Roundup Initial Public Offering (IPO) Radiosurgery Sensus Healthcare LLC Source Type: news

Related Links:

Grading and staging of urothelial neoplasm are the most crucial factors in risk stratification and management; both necessitate optimal accuracy and consistency. Several updates and recommendations have been provided though recent publications of the 4th edition of the World Health Organization classification, the 8th edition of the American Joint Committee on Cancer staging system, and the International Consultation on Urological Diseases –European Association of Urology updates on bladder cancer. Updates and recent studies have provided better insights into and approaches to the challenging scenarios in grading and...
Source: Surgical Pathology Clinics - Category: Pathology Authors: Source Type: research
The American Joint Committee for Cancer eighth edition staging manual incorporated several critical changes regarding staging of testis germ cell tumors, and these changes are summarized and discussed in this article. Further challenges, however, remain, and these are also highlighted.
Source: Surgical Pathology Clinics - Category: Pathology Authors: Source Type: research
This article reflects the aspects that are most influential on daily practice. A brief summary of 3 ancillary commercially available genomic tests is also provided.
Source: Surgical Pathology Clinics - Category: Pathology Authors: Source Type: research
CONCLUSION: Real-world effectiveness of pemetrexed maintenance therapy is similar to that observed in published randomized controlled trials, confirming a role for pemetrexed maintenance in eligible patients in clinical practice. PMID: 30421624 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Authors: Sghaier I, Zidi S, Mouelhi L, Ghazoueni E, Brochot E, Almawi WY, Loueslati BY Abstract BACKGROUND: Chronic infection with hepatitis B (HBV) and C virus (HCV) is linked with a pro-inflammatory state, predisposing to cirrhosis and liver cancer, particularly hepatocellular carcinoma (HCC). A role for toll-like receptor (TLR) signalling in hepatocarcinogenesis was recently documented. We hypothesised a link TLR3 and TLR4 polymorphisms and HCC, as surrogates for the significance of TLR signalling in the promotion and initiation of HCC. MATERIALS &METHODS: We recruited 174 HCV-infected patients, 100 HBV-...
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research
In conclusion, nurses need to provide individualized support and counseling that address the sources of burden. This highlights the benefit of training health care professionals to provide culturally sensitive support based on family caregivers' needs and circumstances.
Source: Holistic Nursing Practice - Category: Nursing Tags: FEATURES Source Type: research
Authors: Korhan P, Yılmaz Y, Bağırsakçı E, Güneş A, Topel H, Carr BI, Atabey N Abstract Hepatocellular carcinoma (HCC) is a major health problem worldwide and most cases are incurable because of late presentation. It is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulation. Portal vein thrombosis (PVT) is a common complication of HCC that is associated with a poor prognosis. Heparin derivatives are widely used in the management of venous thromboembolism (VTE). Among them low molecular weight heparin (LMWH) favorably influen...
Source: Canadian Journal of Gastroenterology - Category: Gastroenterology Tags: Can J Gastroenterol Hepatol Source Type: research
Superficial radiation therapy device developer Sensus Healthcare (NSDQ:SRTSU) today released plans for a global expansion, including new distribution agreements in China, Germany, Mexico, Cuba and Costa Rica. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The Boca Raton, Fla.-based company refers to the technology as superficial radiation therapy, and claims that the tech has been sued to “effectively and safely treat oncological and non-oncological skin conditions.” “Following our new partnersh...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Distribution Oncology Sensus Healthcare LLC Source Type: news
Sensus Healthcare is a medical device company that focuses on providing non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids utilizing superficial radiation technology (SRT). Their proprietary, FDA-cleared SRT technology...
Source: Medgadget - Category: Medical Devices Authors: Tags: Dermatology Exclusive Oncology Source Type: blogs
Sensus Healthcare (NSDQ:SRTSU) priced an $11 million initial public offering yesterday, saying it plans to float 2 million shares at $5.50 apiece starting today. Boca Raton, Fla.-based Sensus said the offering, expected to close June 8, also includes a 300,000-unit over-allotment option for the IPO’s underwriters. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus mak...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Funding Roundup Initial Public Offering (IPO) Radiosurgery Wall Street Beat Sensus Healthcare LLC Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Funding | Health | Keloids | Marketing | Medical Devices | Melanoma | Nonmelanoma Skin Cancer | Skin | Skin Cancer | Sports Medicine | Squamous Cell Carcinoma